Companies Entrada Therapeutics, Inc.
Entrada Therapeutics (TRDA): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Entrada Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $3,735,466FY2023
- $3,891,503FY2024
- $3,837,737FY2025
CEO total pay was $3,837,737 in fiscal 2025, down from $3,891,503 in fiscal 2024.
FY2025: salary $635,000 · bonus $0 · stock awards $1,387,428 · option awards $1,452,059
Executives and directors
Dipal Doshi · CEONatarajan Sethuraman · PresidentNathan Dowden · PresidentBernhardt Zeiher, M.D · Independent DirectorGina Chapman · Independent DirectorKush M. Parmar, M.D., Ph.D · Chair of the BoardMaha Radhakrishnan, M.D · Independent DirectorMary Thistle · Independent DirectorPeter S. Kim, Ph.D · Director
Frequently asked questions
Who was the highest-paid executive at Entrada Therapeutics, Inc. in fiscal 2025?
As disclosed, Dipal Doshi (Chief Executive Officer) was the highest-paid executive at Entrada Therapeutics, Inc. in fiscal 2025, with total compensation of $3,837,737.
How much does Entrada Therapeutics, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Entrada Therapeutics, Inc. reported total board compensation of $329,241 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Dipal Doshi | $635,000 | $0 | $1,387,428 | $1,452,059 | $349,250 | $0 | $14,000 | $3,837,737 |
| Chief Executive Officer | ||||||||
| Natarajan Sethuraman | 520,000 | 0 | 725,952 | 760,363 | 234,000 | 0 | 14,000 | 2,254,315 |
| President of Research and Development | ||||||||
| Nathan Dowden | 499,200 | 0 | 725,952 | 760,363 | 224,640 | 0 | 13,342 | 2,223,497 |
| President and Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Dipal Doshi | $3,837,737 | $3,891,503 | $3,735,466 | ↓ −53,766 |
| Natarajan Sethuraman | 2,254,315 | 1,962,700 | — | ↑ +291,615 |
| Nathan Dowden | 2,223,497 | 2,460,688 | 1,485,455 | ↓ −237,191 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Compensation for named executive officers consists of a combination of base salary, cash bonuses, and long-term incentive compensation in the form of stock options, RSUs and PSUs, designed to be competitive and aligned with the company's business and executive talent requirements.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pay Governance |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Dipal Doshi | Option | — | — | — | — | — | $1,452,059 |
| Dipal Doshi | PSU | — | — | — | — | — | 1,387,428 |
| Nathan Dowden | PSU | — | — | — | — | — | 725,952 |
| Natarajan Sethuraman | Option | — | — | — | — | — | 760,363 |
| Nathan Dowden | Option | — | — | — | — | — | 760,363 |
| Natarajan Sethuraman | PSU | — | — | — | — | — | 725,952 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Dipal Doshi | $0 | $1,387,428 | $1,452,059 | 48.9% |
| Nathan Dowden | 0 | 725,952 | 760,363 | 48.8% |
| Natarajan Sethuraman | 0 | 725,952 | 760,363 | 48.8% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Nathan Dowden | RSU | 1,408 | — | $14,474 |
| Natarajan Sethuraman | RSU | 1,448 | — | 14,885 |
| Nathan Dowden | RSU | 2,816 | — | 28,948 |
| Natarajan Sethuraman | RSU | 2,897 | — | 29,781 |
| Dipal Doshi | RSU | 3,781 | — | 38,869 |
| Nathan Dowden | Option | 4,223 | 11.57 | — |
| Natarajan Sethuraman | Option | 4,345 | 11.57 | — |
| Nathan Dowden | Option | 4,927 | 12 | — |
| Natarajan Sethuraman | Option | 5,070 | 12 | — |
| Natarajan Sethuraman | Option | 6,719 | 12.25 | — |
| Nathan Dowden | Option | 6,719 | 12.25 | — |
| Natarajan Sethuraman | RSU | 7,100 | — | 72,988 |
| Nathan Dowden | RSU | 7,100 | — | 72,988 |
| Dipal Doshi | RSU | 7,562 | — | 77,737 |
| Natarajan Sethuraman | Option | 9,406 | 15.41 | — |
| Nathan Dowden | Option | 9,406 | 15.41 | — |
| Dipal Doshi | Option | 11,344 | 11.57 | — |
| Dipal Doshi | Option | 13,234 | 12 | — |
| Dipal Doshi | Option | 23,516 | 12.25 | — |
| Dipal Doshi | RSU | 24,825 | — | 255,201 |
| Nathan Dowden | RSU | 24,825 | — | 255,201 |
| Nathan Dowden | Option | 28,181 | 13.73 | — |
| Nathan Dowden | RSU | 30,000 | — | 308,400 |
| Dipal Doshi | Option | 32,922 | 15.41 | — |
| Natarajan Sethuraman | RSU | 33,075 | — | 340,011 |
| Natarajan Sethuraman | Option | 37,575 | 13.73 | — |
| Nathan Dowden | RSU | 60,000 | — | 616,800 |
| Natarajan Sethuraman | RSU | 60,800 | — | 625,024 |
| Nathan Dowden | RSU | 60,800 | — | 625,024 |
| Dipal Doshi | RSU | 78,525 | — | 807,237 |
| Natarajan Sethuraman | RSU | 80,000 | — | 822,400 |
| Dipal Doshi | Option | 89,156 | 13.73 | — |
| Natarajan Sethuraman | Option | 90,800 | 11.94 | — |
| Nathan Dowden | Option | 90,800 | 11.94 | — |
| Dipal Doshi | RSU | 100,000 | — | 1,028,000 |
| Dipal Doshi | RSU | 116,200 | — | 1,194,536 |
| Dipal Doshi | Option | 173,400 | 11.94 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Maha Radhakrishnan, M.DIndependent · Audit · Newly elected | $28,538 | $0 | $202,388 | — | $0 | $230,927 |
| Kush M. Parmar, M.D., Ph.DIndependent · Board Chair · Compensation (Chair) · Nominating/Governance (Chair) | 98,209 | 0 | 104,388 | — | 0 | 202,597 |
| Mary ThistleIndependent · Audit (Chair) · Compensation | 63,038 | 0 | 104,388 | — | 0 | 167,427 |
| Gina ChapmanIndependent · Audit · Nominating/Governance | 53,165 | 0 | 104,388 | — | — | 157,553 |
| Bernhardt Zeiher, M.DIndependent · Compensation | 46,291 | 0 | 104,388 | — | 0 | 150,680 |
| Peter S. Kim, Ph.DNot independent | 40,000 | 0 | 104,388 | — | 0 | 144,388 |
| Dipal DoshiEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $250,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 18,000 / 13,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $329,241 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $329,241 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Entrada Therapeutics as a peer
Companies that benchmark against TRDA
6 companies name TRDA as a compensation peer
The list of companies that name TRDA as a peer is temporarily unavailable — recheck shortly.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Entrada Therapeutics, Inc. | 2025 | Dipal Doshi | $635,000 | $1,387,428 | $1,452,059 | $349,250 | $3,837,737 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Nathan Dowden | President & COO | 2026-05-04 | D | 15,000 | $15 | $229,953 | Common | Form 4 ↗ |
| Natarajan Sethuraman | President, Research & Develop. | 2026-05-04 | D | 25,907 | 15 | 398,810 | Common | Form 4 ↗ |
| Nathan Dowden | President & COO | 2026-05-04 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nathan Dowden | President & COO | 2026-05-04 | A | 15,000 | 2 | 26,100 | Common | Form 4 ↗ |
| Bernhardt G. Zeiher | Director | 2026-05-20 | A | 5,000 | 6 | 29,316 | Common, indirect | Form 4 ↗ |
| Bernhardt G. Zeiher | Director | 2026-06-10 | A | 19,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter S. Kim | Director | 2026-06-10 | A | 19,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Maha Radhakrishnan | Director | 2026-06-10 | A | 19,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gina Chapman | Director | 2026-06-10 | A | 19,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kush Parmar | Director | 2026-06-10 | A | 19,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mary Thistle | Director | 2026-06-10 | A | 19,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kush Parmar | Director | 2026-07-30 | D | 114,756 | 7 | 795,259 | Common, indirect | Form 4 ↗ |
| 5AM Ventures V, L.P. | Greater-than-10% holder | 2026-07-30 | D | 114,756 | 7 | 795,259 | Common, indirect | Form 4 ↗ |
| Kush Parmar | Director | 2026-07-31 | D | 1,718 | 7 | 11,768 | Common | Form 4 ↗ |
| 5AM Ventures V, L.P. | Greater-than-10% holder | 2026-07-31 | D | 1,718 | 7 | 11,768 | Common, indirect | Form 4 ↗ |
| 5AM Ventures V, L.P. | Greater-than-10% holder | 2026-08-06 | D | 10,494 | 7 | 73,458 | Common, indirect | Form 4 ↗ |
| Kush Parmar | Director | 2026-08-06 | D | 10,494 | 7 | 73,458 | Common, indirect | Form 4 ↗ |
| 5AM Ventures V, L.P. | Greater-than-10% holder | 2026-08-07 | D | 52,317 | 7 | 358,371 | Common, indirect | Form 4 ↗ |
| Kush Parmar | Director | 2026-08-07 | D | 52,317 | 7 | 358,371 | Common | Form 4 ↗ |
| Kush Parmar | Director | 2026-08-10 | D | 92,444 | 7 | 647,108 | Common, indirect | Form 4 ↗ |
| MPM BIOVENTURES 2018, L.P. | Greater-than-10% holder | 2026-08-24 | D | 21,623 | 7 | 158,713 | Common, indirect | Form 4 ↗ |
| MPM BioVentures 2014, L.P. | Greater-than-10% holder | 2026-08-24 | D | 21,623 | 7 | 158,713 | Common, indirect | Form 4 ↗ |
| MPM BioVentures 2014, L.P. | Greater-than-10% holder | 2026-08-25 | D | 26,522 | 8 | 199,976 | Common, indirect | Form 4 ↗ |
| MPM BIOVENTURES 2018, L.P. | Greater-than-10% holder | 2026-08-25 | D | 26,522 | 8 | 199,976 | Common, indirect | Form 4 ↗ |
| MPM BioVentures 2014, L.P. | Greater-than-10% holder | 2026-08-26 | D | 14,569 | 7 | 102,857 | Common, indirect | Form 4 ↗ |
| MPM BIOVENTURES 2018, L.P. | Greater-than-10% holder | 2026-08-26 | D | 14,569 | 7 | 102,857 | Common, indirect | Form 4 ↗ |
| MPM BioVentures 2014, L.P. | Greater-than-10% holder | 2026-08-27 | D | 38,922 | 7 | 280,238 | Common, indirect | Form 4 ↗ |
| MPM BIOVENTURES 2018, L.P. | Greater-than-10% holder | 2026-08-27 | D | 38,922 | 7 | 280,238 | Common, indirect | Form 4 ↗ |
| MPM BIOVENTURES 2018, L.P. | Greater-than-10% holder | 2026-08-28 | D | 3,733 | 7 | 26,168 | Common, indirect | Form 4 ↗ |
| MPM BioVentures 2014, L.P. | Greater-than-10% holder | 2026-08-28 | D | 3,733 | 7 | 26,168 | Common, indirect | Form 4 ↗ |
| MPM BioVentures 2014, L.P. | Greater-than-10% holder | 2026-08-31 | D | 44,259 | 7 | 309,370 | Common, indirect | Form 4 ↗ |
| MPM BIOVENTURES 2018, L.P. | Greater-than-10% holder | 2026-08-31 | D | 44,259 | 7 | 309,370 | Common, indirect | Form 4 ↗ |
| MPM BioVentures 2014, L.P. | Greater-than-10% holder | 2026-09-01 | D | 29,088 | 7 | 205,361 | Common, indirect | Form 4 ↗ |
| MPM BIOVENTURES 2018, L.P. | Greater-than-10% holder | 2026-09-01 | D | 29,088 | 7 | 205,361 | Common, indirect | Form 4 ↗ |
| Dipal Doshi | Director | 2026-09-02 | D | 8,724 | 7 | 62,323 | Common | Form 4 ↗ |
| Natarajan Sethuraman | President, Research & Develop. | 2026-09-02 | D | 2,079 | 7 | 14,852 | Common | Form 4 ↗ |
| Kory James Wentworth | Chief Financial Officer | 2026-09-02 | D | 1,733 | 7 | 12,380 | Common | Form 4 ↗ |
| Nathan Dowden | President & COO | 2026-09-02 | D | 2,528 | 7 | 18,060 | Common | Form 4 ↗ |
| MPM BioVentures 2014, L.P. | Greater-than-10% holder | 2026-09-02 | D | 25,131 | 7 | 180,692 | Common, indirect | Form 4 ↗ |
| MPM BIOVENTURES 2018, L.P. | Greater-than-10% holder | 2026-09-02 | D | 25,131 | 7 | 180,692 | Common, indirect | Form 4 ↗ |
| MPM BIOVENTURES 2018, L.P. | Greater-than-10% holder | 2026-09-03 | D | 32,263 | 7 | 231,326 | Common, indirect | Form 4 ↗ |
| MPM BioVentures 2014, L.P. | Greater-than-10% holder | 2026-09-03 | D | 32,263 | 7 | 231,326 | Common, indirect | Form 4 ↗ |
| MPM BioVentures 2014, L.P. | Greater-than-10% holder | 2026-09-04 | D | 38,500 | 7 | 273,735 | Common, indirect | Form 4 ↗ |
| MPM BIOVENTURES 2018, L.P. | Greater-than-10% holder | 2026-09-04 | D | 38,500 | 7 | 273,735 | Common, indirect | Form 4 ↗ |
| MPM BIOVENTURES 2018, L.P. | Greater-than-10% holder | 2026-09-08 | D | 192,500 | 7 | 1,426,425 | Common, indirect | Form 4 ↗ |
| MPM BioVentures 2014, L.P. | Greater-than-10% holder | 2026-09-08 | D | 192,500 | 7 | 1,426,425 | Common, indirect | Form 4 ↗ |
| MPM BioVentures 2014, L.P. | Greater-than-10% holder | 2026-09-09 | D | 28,837 | 7 | 205,608 | Common, indirect | Form 4 ↗ |
| MPM BIOVENTURES 2018, L.P. | Greater-than-10% holder | 2026-09-09 | D | 28,837 | 7 | 205,608 | Common, indirect | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (69 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Dipal Doshi. DEF 14A, filed 2026-04-24. Section “2025 Summary Compensation Table” · page 45. As printed: 3,837,737. View filing ↗
- Section 01, Natarajan Sethuraman. DEF 14A, filed 2026-04-24. Section “2025 Summary Compensation Table”. As printed: 2,254,315. View filing ↗
- Section 01, Nathan Dowden. DEF 14A, filed 2026-04-24. Section “2025 Summary Compensation Table”. As printed: 2,223,497. View filing ↗
- Section 03, Dipal Doshi Option. DEF 14A, filed 2026-04-24. Section “ALL OTHER COMPENSATION (” · grants of plan-based awards table. View filing ↗
- Section 03, Dipal Doshi PSU. DEF 14A, filed 2026-04-24. Section “ALL OTHER COMPENSATION (” · grants of plan-based awards table. View filing ↗
- Section 03, Nathan Dowden PSU. DEF 14A, filed 2026-04-24. Section “ALL OTHER COMPENSATION (” · grants of plan-based awards table. View filing ↗
- Section 03, Natarajan Sethuraman Option. DEF 14A, filed 2026-04-24. Section “ALL OTHER COMPENSATION (” · grants of plan-based awards table. View filing ↗
- Section 03, Nathan Dowden Option. DEF 14A, filed 2026-04-24. Section “ALL OTHER COMPENSATION (” · grants of plan-based awards table. View filing ↗
- Section 03, Natarajan Sethuraman PSU. DEF 14A, filed 2026-04-24. Section “ALL OTHER COMPENSATION (” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-02-26. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Maha Radhakrishnan, M.D. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 230,927. View filing ↗
- Section 08, Kush M. Parmar, M.D., Ph.D. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 202,597. View filing ↗
- Section 08, Mary Thistle. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 167,427. View filing ↗
- Section 08, Gina Chapman. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 157,553. View filing ↗
- Section 08, Bernhardt Zeiher, M.D. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 150,680. View filing ↗
- Section 08, Peter S. Kim, Ph.D. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 144,388. View filing ↗
- Section 08, Dipal Doshi. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Nathan Dowden 2026-05-04. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Natarajan Sethuraman 2026-05-04. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nathan Dowden 2026-05-04. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nathan Dowden 2026-05-04. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bernhardt G. Zeiher 2026-05-20. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bernhardt G. Zeiher 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter S. Kim 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Maha Radhakrishnan 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gina Chapman 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kush Parmar 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mary Thistle 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kush Parmar 2026-07-30. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, 5AM Ventures V, L.P. 2026-07-30. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kush Parmar 2026-07-31. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, 5AM Ventures V, L.P. 2026-07-31. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, 5AM Ventures V, L.P. 2026-08-06. Form 4, filed 2026-08-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kush Parmar 2026-08-06. Form 4, filed 2026-08-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, 5AM Ventures V, L.P. 2026-08-07. Form 4, filed 2026-08-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kush Parmar 2026-08-07. Form 4, filed 2026-08-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kush Parmar 2026-08-10. Form 4, filed 2026-08-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MPM BIOVENTURES 2018, L.P. 2026-08-24. Form 4, filed 2026-08-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MPM BioVentures 2014, L.P. 2026-08-24. Form 4, filed 2026-08-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MPM BioVentures 2014, L.P. 2026-08-25. Form 4, filed 2026-08-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MPM BIOVENTURES 2018, L.P. 2026-08-25. Form 4, filed 2026-08-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MPM BioVentures 2014, L.P. 2026-08-26. Form 4, filed 2026-08-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MPM BIOVENTURES 2018, L.P. 2026-08-26. Form 4, filed 2026-08-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MPM BioVentures 2014, L.P. 2026-08-27. Form 4, filed 2026-08-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MPM BIOVENTURES 2018, L.P. 2026-08-27. Form 4, filed 2026-08-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MPM BIOVENTURES 2018, L.P. 2026-08-28. Form 4, filed 2026-08-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MPM BioVentures 2014, L.P. 2026-08-28. Form 4, filed 2026-08-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MPM BioVentures 2014, L.P. 2026-08-31. Form 4, filed 2026-08-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MPM BIOVENTURES 2018, L.P. 2026-08-31. Form 4, filed 2026-08-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MPM BioVentures 2014, L.P. 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MPM BIOVENTURES 2018, L.P. 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dipal Doshi 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Natarajan Sethuraman 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kory James Wentworth 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nathan Dowden 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MPM BioVentures 2014, L.P. 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MPM BIOVENTURES 2018, L.P. 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MPM BIOVENTURES 2018, L.P. 2026-09-03. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MPM BioVentures 2014, L.P. 2026-09-03. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MPM BioVentures 2014, L.P. 2026-09-04. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MPM BIOVENTURES 2018, L.P. 2026-09-04. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MPM BIOVENTURES 2018, L.P. 2026-09-08. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MPM BioVentures 2014, L.P. 2026-09-08. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MPM BioVentures 2014, L.P. 2026-09-09. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MPM BIOVENTURES 2018, L.P. 2026-09-09. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 329,241 + equity 0 + all other 0 = 329,241, summed across the director compensation table rows.
- Entrada Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Entrada Therapeutics, Inc.'s own proxy. As printed: 3,837,737. View filing ↗